We studied the effect of any steroid use in patients with advanced non–small-cell lung cancer receiving immunotherapy with first-line pembrolizumab, an anti-programmed cell death 1 monoclonal antibody. The use of any steroid before or during treatment was associated with a 86% increase in the risk of progression and a 2.3-fold increase in the risk of death, independently of all established prognostic factors, including the presence of central nervous system metastasis.
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy
Roila F.;Galetta D.;Metro G.
2021
Abstract
We studied the effect of any steroid use in patients with advanced non–small-cell lung cancer receiving immunotherapy with first-line pembrolizumab, an anti-programmed cell death 1 monoclonal antibody. The use of any steroid before or during treatment was associated with a 86% increase in the risk of progression and a 2.3-fold increase in the risk of death, independently of all established prognostic factors, including the presence of central nervous system metastasis.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
